Real World Evidence Clinical Utility Study of KidneyIntelX
Age: 23 years - 66+
Healthy Subjects: No
Recruitment Status: Recruiting
Start Date: March 02, 2021
End Date: December 01, 2026
- Individuals with Type 2 diabetes and concurrent chronic (diabetic) kidney disease (G3a-G3b or G1-G2, A2-A3) per KDIGO CKD staging.
- Patents without the appropriate characteristics as identified in the KidneyIntelX intended use population.
- Patients with eGFR <30 or ≥ 60 ml/min/1.73m2 without albuminuria.
- Patients with ESRD or on renal recovery treatments at time of enrollment.
- Patients who are pregnant at the time of enrollment.
- Patients who are currently hospitalized.
- Patients without minimum 6 month pre-baseline KidneyIntelX medical history.
- Patients who are currently on Enbrel.